Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Sepsis Outcome Programme (GnSOP) Annual Report 2020

Authors

  • Jan M Bell Australian Group on Antimicrobial Resistance, Adelaide, South Australia, Australia
  • Alicia Fajardo Lubian Westmead Institute for Medical Research, Westmead, New South Wales, Australia; University of Sydney, New South Wales, Australia
  • Sally R Partridge Westmead Institute for Medical Research, Westmead, New South Wales, Australia; University of Sydney, New South Wales, Australia; Westmead Hospital, Westmead, New South Wales, Australia
  • Thomas Gottlieb University of Sydney, New South Wales, Australia; Department of Microbiology and Infectious Diseases, Concord Hospital, Concord, New South Wales, Australia
  • Jonathan Iredell Westmead Institute for Medical Research, Westmead, New South Wales, Australia; University of Sydney, New South Wales, Australia; Westmead Hospital, Westmead, New South Wales, Australia
  • Denise A Daley Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
  • Geoffrey W Coombs Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia; Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

DOI:

https://doi.org/10.33321/cdi.2022.46.11

Keywords:

Australian Group on Antimicrobial Resistance (AGAR), antimicrobial resistance, bacteraemia, gram-negative, Escherichia coli, Enterobacter, Klebsiella

Abstract

The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. The 2020 survey was the eighth year to focus on bloodstream infections caused by Enterobacterales, and the sixth year in which Pseudomonas aeruginosa and Acinetobacter species were included.

Eight thousand seven hundred and fifty-two isolates, comprising Enterobacterales (7,871, 89.9%), P. aeruginosa (771, 8.8%) and Acinetobacter species (110, 1.3%), were tested using commercial automated methods. The results were analysed using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2021). Of the key resistances, resistance to the third-generation cephalosporin ceftriaxone was found in 13.5%/13.5% (CLSI/EUCAST criteria) of Escherichia coli and 8.7%/8.7% of Klebsiella pneumoniae. Resistance rates to ciprofloxacin were 16.1%/16.1% for E. coli; 9.9%/9.9% for K. pneumoniae; 5.8%/5.8% for Enterobacter cloacae complex; and 4.5%/8.1% for P. aeruginosa. Resistance rates to piperacillin-tazobactam were 2.5%/6.6%; 3.9%/12.5%; 16.9%/26.3%; and 5.5%/14.4% for the same four species respectively. Thirty-two isolates from 32 patients were shown to harbour at least one carbapenemase gene: 19 blaIMP-4, three blaGES-5, two blaNDM-1, two blaNDM-5, two blaOXA-48, two blaOXA-181, one blaIMI-1, and one blaOXA-23+NDM-1.

Downloads

Download data is not yet available.

References

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 31st ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania, USA; 2021.

European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints – breakpoints and guidance. Version 11.0, 6 January 2021. Available at: http://www.eucast.org/clinical_breakpoints/.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81. doi: https://doi.org/10.1111/j.1469-0691.2011.03570.x.

Ellem J, Partridge SR, Iredell JR. Efficient direct extended-spectrum β-lactamase detection by multiplex real-time PCR: accurate assignment of phenotype by use of a limited set of genetic markers. J Clin Microbiol. 2011;49(8):3074–7. doi: https://doi.org/10.1128/JCM.02647-10.

Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor. San Francisco: Github; 2020. Available from: https://github.com/tseemann/nullarbor.

Seemann T. Abricate. San Francisco: Github; 2020. Available from: https://github.com/tseemann/abricate.

National Center for Biotechnology Information (NCBI). AMRFinderPlus. [Website.] Bethesda; United States National Library of Medicine, NCBI: 2020. Available from: https://ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/.

Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, Keane JA et al. ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads. Microb Genom. 2017;3(10):e000131. doi: https://doi.org/10.1099/mgen.0.000131.

Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A et al. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Res. 2020;48(D1):D517–25. doi: https://doi.org/10.1093/nar/gkz935.

Turnidge JD, Gottlieb T, Mitchell D, Pearson J, Bell JM, on behalf of the Australian Group for Antimicrobial Resistance (AGAR). Gram-negative Survey: 2011 Antimicrobial Susceptibility Report. AGAR; 2012. Available from: http://agargroup.org.au/wp-content/uploads/2017/08/AGAR-GNB11-Report-FINAL.pdf.

Sheng WH, Badal RE, Hsueh PR, on behalf of the SMART Program. Distribution of extended-spectrum ß-lactamases, AmpC ß-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013;57(7):2981–8. doi: https://doi.org/10.1128/AAC.00971-12.

European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report 2019. Stockholm: ECDC; 18 November 2020. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2019.

European Centre for Disease Prevention and Control. Additional tables – antimicrobial resistance in the EU/EEA 2019. Stockholm: ECDC; 18 November 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Additional-tables-EUEEA-population-weighted-mean-2019.pdf.

Downloads

Published

28/03/22

How to Cite

Bell, Jan M, Alicia Fajardo Lubian, Sally R Partridge, Thomas Gottlieb, Jonathan Iredell, Denise A Daley, and Geoffrey W Coombs. 2022. “ Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-Negative Sepsis Outcome Programme (GnSOP) Annual Report 2020”. Communicable Diseases Intelligence 46 (March). https://doi.org/10.33321/cdi.2022.46.11.

Issue

Vol. 46 (2022)

Section

Annual report

Categories

License

Copyright (c) 2022 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 > >>